Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 16 clinical trials
None
Hepatic Impairment Study for Lorlatinib in Cancer Patients

This is a phase 1 study in advanced cancer patients with varied hepatic fucntions to evaluate the potential effect of hepatic impairment on pharmacokinetics and safety of lorlatinib and provide

  • 0 views
  • 25 Sep, 2021
  • 19 locations
None
Lorlatinib After Failure of First-line TKI in Patients With Advanced ROS1-positive NSCLC (ALBATROS)

to these tyrosine kinase inhibitors. Lorlatinib is a new and potent ROS1 / ALK inhibitor optimized to penetrate the blood-brain barrier. A recent study has investigated the activity of

  • 0 views
  • 07 Jun, 2021
  • 39 locations
None
Lorlatinib After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients With Advanced ALK-positive Non-small Cell Lung Cancer

Crizotinib is a first-generation ALK tyrosine kinase inhibitor (ITK-ALK). It is the standard first-line treatment for patients with advanced NSCLC with ALK gene rearrangement. Alectinib, ceritinib and brigatinib are second-generation ITK-ALK. They have been shown to be effective in the first line of treatment in randomized trials. Alectinib has shown …

  • 0 views
  • 26 Jan, 2021
  • 30 locations
None
NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922)

Lorlatinib is a novel inhibitor across ALK variants, including those resistant to crizotinib. In this first pediatric phase 1 trial of lorlatinib, the drug will be utilized as a single agent and

avid
refractory neuroblastoma
catecholamines
topotecan
cancer
  • 158 views
  • 02 Feb, 2021
  • 15 locations
None
Activity of Lorlatinib Based on ALK Resistance Mutations Detected on Blood in ALK Positive NSCLC Patients

have been developed to identify the mutations in the blood. Lorlatinib is a drug that inhibits ALK and has already been identified to be able to control the tumour growth when ALK mutations are

serum bilirubin level
lung carcinoma
metastasis
brigatinib
alectinib
  • 0 views
  • 21 Jul, 2021
  • 21 locations
None
Study of Lorlatinib In Participants With Anaplastic Lymphoma Kinase (ALK) -Positive NSCLC

A Phase 4 study to assess Overall and Intracranial Response Rate of single-agent lorlatinib in participants with advanced ALK-positive NSCLC whose disease has progressed on alectinib or

lorlatinib
anaplastic lymphoma
chemotherapy regimen
lymphoma
ceritinib
  • 0 views
  • 15 Nov, 2021
  • 40 locations
None
Lorlatinib Combinations in Lung Cancer

This research study is evaluating Lorlatinib in combination with Crizotinib, Binimetinib, or TNO155 as a possible treatment for either anaplastic lymphoma kinase (ALK)-positive lung cancer or

lorlatinib
proto-oncogene tyrosine-protein kinase ros
lung carcinoma
kinase inhibitor
crizotinib
  • 0 views
  • 19 Mar, 2021
None
Study of Lorlatinib in ROS1 Rearranged NSCLC

This is a phase II, multi-center, single arm study of lorlarinib as a single agent in patients with ROS1-rearranged advanced NSCLC.

platinum doublet
proto-oncogene tyrosine-protein kinase ros
measurable disease
ROS1
recurrent non-small cell lung cancer
  • 0 views
  • 25 Jan, 2021
  • 1 location
None
A Study of Oral Lorlatinib in Patients With Relapsed ALK Positive Lymphoma

The purpose of this study is to define the objective response rates (ORR) of Lorlatinib in subjects with ALK+ lymphomas resistant or refractory to ALK inhibitors.

  • 0 views
  • 10 Oct, 2021
  • 1 location
None
Temodar Plus Tyrosine Kinase Inhibitors for Progressive CNS Disease

This trial is testing two novel combinations (temozolomide plus osimertinib OR temozolomide plus lorlatinib) which have not been evaluated in clinical trials. Thus, the exact benefits of these

  • 0 views
  • 16 Mar, 2021
  • 1 location